Faruqi and Faruqui, LLP Logo
Share this page

Acorda Therapeutics Inc. (ACOR)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc. (“Acorda” or the “Company”) (NASDAQ:ACOR).

Specifically, on November 15, 2017, Acorda announced that it had identified seven cases of sepsis in patients, five of which were fatal, during the final-stage trial studies of the Company’s treatment for Parkinson’s disease, tozadenant.  The Company also announced that new patient enrollment in the trial would be stopped.

On this news, Acorda’s share price significantly declined.

If you invested in Acorda stock or options and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Acorda Therapeutics Inc. (ACOR)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 11/16/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.